MimiVax Phase 2 study of SurVaxM in combination with pembrolizumab opens for recurrent glioblastoma patients.
A syringe with the needle point to the vaccine vial on the colorful abstract background

MimiVax Phase 2 study of SurVaxM in combination with pembrolizumab opens for recurrent glioblastoma patients.

Buffalo, NY - MIMIVAX LLC, a clinical-stage biotechnology company in Buffalo, N.Y., USA, developing immunotherapeutics for cancer and autoimmune diseases, announced a clinical collaboration to assess the combination of SurVaxM…

Continue Reading MimiVax Phase 2 study of SurVaxM in combination with pembrolizumab opens for recurrent glioblastoma patients.
MimiVax Advances Toward New Clinical Trial for Brain Cancer Immunotherapy SurVaxM
Brain cancer awareness, grey ribbon on helping hand

MimiVax Advances Toward New Clinical Trial for Brain Cancer Immunotherapy SurVaxM

https://www.prweb.com/releases/roswell_park_spinoff_company_advances_toward_new_clinical_trial_for_brain_cancer_immunotherapy_survaxm/prweb16737735.htm MimiVax LLC and Roswell Park to launch large clinical trial at centers in U.S. & abroad following major licensing deal MimiVax LLC secures $10 million upfront in licensing dealLarge…

Continue Reading MimiVax Advances Toward New Clinical Trial for Brain Cancer Immunotherapy SurVaxM

MimiVax LLC and Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. announce exclusive licensing agreement on SurVaxM for glioblastoma treatment in China

Buffalo-based clinical-stage biotechnology company MimiVax, a Roswell Park Comprehensive Cancer Center spinoff, set to work with leading healthcare group in China to provide promising immunotherapy BUFFALO, N.Y. and SHANGHAI, Nov. 18, 2019 /PRNewswire/ --…

Continue Reading MimiVax LLC and Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. announce exclusive licensing agreement on SurVaxM for glioblastoma treatment in China

George Washington University Researchers presenting at 2019 MGFA Scientific Session, AANEM Annual Meeting

Linda Kusner, PhD will present new data utilizing MV2C2 antibodies in Myasthenia Gravis. “Survivin is a negative regulator of apoptosis in myasthenia gravis: a human and animal model study” (October 16,…

Continue Reading George Washington University Researchers presenting at 2019 MGFA Scientific Session, AANEM Annual Meeting
MimiVax to present results of SurVaxM immunotherapy in glioblastoma at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting
3d rendered medically accurate illustration of white blood cells attacking a cancer cell

MimiVax to present results of SurVaxM immunotherapy in glioblastoma at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting

Clinical-stage biotechnology company also sharing its accomplishments to date and future plans at the 2019 Biotechnology Innovation Organization (BIO) International Convention BUFFALO, N.Y., May 29, 2019 /PRNewswire/ -- MimiVax LLC, a clinical-stage…

Continue Reading MimiVax to present results of SurVaxM immunotherapy in glioblastoma at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting
MimiVax awarded Orphan Drug Designation by US FDA for SurVaxM to treat glioblastoma patients
pharmaceutical industry. Production line machine conveyor with glass bottles ampoules at factory

MimiVax awarded Orphan Drug Designation by US FDA for SurVaxM to treat glioblastoma patients

Novel immunotherapy, SurVaxM, being developed as treatment for glioblastoma BUFFALO, N.Y. — The U.S. Food and Drug Administration has awarded orphan drug status to a promising immunotherapy vaccine developed at…

Continue Reading MimiVax awarded Orphan Drug Designation by US FDA for SurVaxM to treat glioblastoma patients

Clinical Trial Will Explore First-Time Use of SurVaxM Vaccine in Combination with REVLIMID® to Treat Rare Blood Cancer

Immunotherapy Developed at Roswell Park Being Tested as Treatment for Multiple Myeloma BUFFALO, N.Y. — An immune-based therapy developed at Roswell Park Cancer Institute (RPCI) is moving forward with its…

Continue Reading Clinical Trial Will Explore First-Time Use of SurVaxM Vaccine in Combination with REVLIMID® to Treat Rare Blood Cancer
SurVaxM Phase I Completed
A syringe with the needle point to the vaccine vial on the colorful abstract background

SurVaxM Phase I Completed

Phase I clinical trial results of SurVaxM presented at AACR Annual Meeting 2015 in Philadelphia BUFFALO, N.Y. — A first-of-its kind cancer vaccine, SurVaxM, has demonstrated safety and tolerability in…

Continue Reading SurVaxM Phase I Completed